Affordable Access

deepdyve-link
Publisher Website

Application and validation of an advanced gastrointestinal in vitro model for the evaluation of drug product performance in pharmaceutical development.

Authors
  • Barker, Richard
  • Abrahamsson, Bertil
  • Kruusmägi, Martin
Type
Published Article
Journal
Journal of Pharmaceutical Sciences
Publisher
Elsevier
Publication Date
Nov 01, 2014
Volume
103
Issue
11
Pages
3704–3712
Identifiers
DOI: 10.1002/jps.24177
PMID: 25223814
Source
Medline
Keywords
License
Unknown

Abstract

Methods to understand and predict the oral bioavailability of drug products are a prioritized research area within the pharmaceutical industry. Models to predict oral bioavailability have the potential to reduce risk, time, and cost in development as well as decrease the need for animal studies. The TNO intestinal model (TIM-1) is an advanced dissolution model deployed by AstraZeneca since 2008. This article presents a systematic evaluation of TIM-1 against in vivo data. The relative performance of compounds and formulations tested in TIM-1 and in vivo was compared both by a qualitative analysis and a linear regression analysis of relative exposure measures between test and reference formulations in TIM-1 and in vivo. The TIM-1 correctly predicted in vivo rank order in 84% and 79% of cases for AUC and Cmax , respectively, when using the 3-h time point. There was only one case for Cmax in which TIM-1 did not predict an in vivo difference. The correlation coefficient (R(2) ) between relative (test vs. reference formulations) fraction available in TIM-1 after 3 h and AUC was 0.78. Thus, this study suggests that the TIM-1 system can be used to assess the risk for significant differences in exposure between formulations and compound modifications.

Report this publication

Statistics

Seen <100 times